ESPE Yearbook of Paediatric Endocrinology

J Clin Endocrinol Metab. 2020; 105: e3730–41. https://pubmed.ncbi.nlm.nih.gov/32706856/This retrospective analysis of the Pfizer International Growth Database (KIGS) included 1149 cancer survivors with growth hormone deficiency (GHD) who had received growth hormone therapy (GHT) for at least 5 years. Patients with craniopharyngioma had the best 5-year growth response ...

To read the full abstract: J Pediatr. 2018 Jul;198:260–264This study aimed to analyze growth hormone (GH) doses and first-year growth response in prepubertal patients with the combination of type 1 diabetes (T1D) and growth hormone deficiency (GHD).A total of 69 patients with T1D and GHD treated with GH have been enrolled in KIGS (Pfizer International Growth D...

To read the full abstract: J Pediatr 2018; 198: 260-264The incidence of T1DM in children <15 years is increasing at an overall annual relative rate of 3.9% (95% CI 3.6-4.2) [11]. The prevalence of GHD is estimated at approximately 1:4000 to 1:10000 [12-14]. Management of the very rare patients who have both T1DM and GHD raises questions of efficacy and safety of ...

Diabetes Care. 2020; 43:82–89. doi: 10.2337/dc19-0747.It is often difficult to identify maturity-onset diabetes of the young (MODY) in pediatric patients close to diabetes onset. Hence, misdiagnosis and unnecessary insulin treatment are still common.This study reports the discriminatory clinical features at diabetes onset in Swedish pediatric patients (age 1–18 y...

Brief summary: This study reports data from the full Kabi/Pfizer International Growth Database (KIGS), a large international database including 83803 children treated with rhGH for GHD and non-GHD conditions. The data confirm that rhGH is effective in increasing short-term height gain and adult height in various conditions and validate rhGH safety, with no new serious adverse events reported.KIGS (Kabi/Pfizer International Growth Database), first establi...